Holen Sie sich die Stockscreener-App
184.18
0.00%
0.00
Vorhandelsmarkt:
184.45
0.27
+0.15%
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Why is Axsome (AXSM) down 6.6% since last earnings report? - MSN
axsm stock overview: Axsome Therapeutics (AXSM) - Bitget
AXSM SEC FilingsAxsome Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Guggenheim Maintains Axsome Therapeutics (AXSM) Buy Recommendation - MSN
Axsome Therapeutics, Inc. (AXSM) Stock Price, News, Quote & History - Yahoo Finance
Update Recap: How does Axsome Therapeutics Inc compare to its peers2026 Outlook & AI Forecasted Stock Moves - baoquankhu1.vn
Axsome Is Priced For Perfection Ahead Of Auvelity's Alzheimer's Agitation Decision - Seeking Alpha
Iridian Asset Management LLC CT Sells 9,770 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Aug Big Picture: Does Axsome Therapeutics Inc outperform in volatile markets2026 EndofMonth & High Accuracy Investment Signals - baoquankhu1.vn
Is Axsome Therapeutics (AXSM) Still Attractively Priced After Its 72% One-Year Surge - Yahoo Finance
Axsome Faces Key Auvelity FDA Call And Insider Sentiment Test - Yahoo Finance
Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool
Axsome Therapeutics (AXSM) Is Up 6.2% After Highlighting Key FDA Decision on Auvelity - simplywall.st
Today's Analyst Ratings for Axsome Therapeutics (AXSM) | AXSM St - GuruFocus
UBS Group Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - MarketBeat
Axsome Therapeutics Upside Tied to Auvelity FDA Decision, $2 Billion Sales Opportunity Seen, UBS Says - marketscreener.com
UBS raises Axsome Therapeutics price target on Auvelity outlook By Investing.com - Investing.com Canada
UBS Adjusts Axsome Therapeutics Price Target to $259 From $251, Maintains Buy Rating - marketscreener.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Sidley Represents Axsome Therapeutics in its Acquisition of Global Rights to Balipodect from Takeda - Legal Desire Media and Insights
Franklin Street Advisors Inc. NC Invests in Axsome Therapeutics - National Today
Why Axsome Therapeutics Stock Is Suddenly Sinking - TipRanks
Franklin Street Advisors Inc. NC Makes New Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4 - Sahm
Axsome’s Decade of 33% Returns Puts Focus on $16 Billion Pipeline - NAI500
AXSM Technical Analysis | Trend, Signals & Chart Patterns | AXSOME THERAPEUTICS INC (NASDAQ:AXSM) - ChartMill
Is This Healthcare Stock a Millionaire Maker? - AOL.com
(AXSM) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
RBC Capital Adjusts Price Target on Axsome Therapeutics to $221 From $222, Maintains Outperform Rating - marketscreener.com
Axsome Therapeutics (AXSM) Q2 2024 earnings summary - Quartr
AXSM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Balipodect Licensing Deal From Takeda - Sahm
Element Squared LLC Invests $1.48 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Acquisition Play Signals A Bold Push Into Schizophrenia Market! - Smartkarma
Axsome stock climbs on schizophrenia drug deal with Takeda - MSN
Axsome Acquires Global Rights to TAK-063 from Takeda - Intellectia AI
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $260 - Moomoo
Axsome Therapeutics acquires Takeda’s selective PDE10A inhibitor balipodect - The Pharma Letter
AXSM Technical Analysis & Stock Price Forecast - intellectia.ai
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions - Sahm
Biopharma bites: Axsome adds an asset from Takeda, IO Biotech's farewell, and Evotec's new commercial leader - FirstWord Pharma
Takeda (TAK) Sells Rights to Schizophrenia Drug to Axsome - GuruFocus
Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda - Benzinga
Axsome Therapeutics Acquires Global Rights to Balipodect, a Selective PDE10A Inhibitor, for Schizophrenia and Neuropsychiatric Disorders 1 - minichart.com.sg
Axsome acquires global rights to Takeda’s balipodect - TipRanks
Axsome acquires global rights to balipodect from Takeda By Investing.com - Investing.com Canada
Axsome Therapeutics Acquires Exclusive Global Rights to Balipodect from Takeda - marketscreener.com
Axsome Therapeutics acquires balipodect, gains global rights and plans Phase 3-enabling work for schizophrenia - TradingView — Track All Markets
Axsome acquires global rights to balipodect from Takeda - Investing.com
Axsome Therapeutics (NASDAQ: AXSM) secures global rights to balipodect - Stock Titan
Axsome Therapeutics Incto Begin Phase 3 Tr - Moomoo
Axsome Therapeutics Acquires Selective PDE10A Inhibitor - GlobeNewswire
Axsome Therapeutics (AXSM) Valuation Check After Recent Share Price Cooling - Yahoo Finance
Dow Update: How does Axsome Therapeutics Inc compare to its peersWeekly Trade Analysis & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Hennion & Walsh Asset Management Inc. Cuts Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
(AXSM) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):